PF-07259955, a topical “soft” JAK inhibitor, had the shortest stay in the clinic. Pfizer began a phase 1 trial of the asset and another drug with the same mechanism of action, PF-07295324, in healthy volunteers in February. Having wrapped up the study in August, Pfizer has decided it can do without PF-07259955. The other soft JAK inhibitor, which is designed for minimal systemic exposure, remains in development.
Companies including Pfizer and Novartis have identified soft, topically administered JAK inhibitorsJAK inhibitors as a way to achieve strong therapeutic effects in the skin without causing the systemic effects associated with oral administration. Novartis dropped its asset, CEE321, earlier this year after seeing phase 1 data, but ongoing development of PF-07295324 means Pfizer remains in the race to challenge Incyte’s Opzelura.
Pfizer has also given the heave-ho to PF-07202954 in NASH with liver fibrosis. The drugmaker tested single and repeat doses of the DGAT2 inhibitorDGAT2 inhibitor in 12 healthy volunteers last year, enrolling far fewer than the 88 subjects that it initially targeted.
Finally, Pfizer formally discontinued the cardiovascular disease candidate PF-07265803. News that work on the program would end emerged in August when Pfizer revealed a phase 3 trial had failed an interim futility analysis.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.